Finding markers in patients with head and neck cancer on immunotherapy
Part of Cancer clinical trials.
This trial looks for specific signs in your blood and tumor tissue that may show how well immunotherapy is working for recurrent or metastatic head and neck cancer. It aims to help doctors personalize treatment in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of head and neck cancer (squamous cell carcinoma) that started in the mouth, throat, or voice box
- Your cancer has come back or spread after initial treatment, and your doctor has recommended immunotherapy
- You are able to speak French
- You have health insurance in France
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is collecting information and blood samples from people with head and neck cancer that cannot be cured. It aims to learn more about the cancer and find better ways to treat it.
This study collects tissue from people with newly diagnosed head and neck squamous cell cancer and grows “mini tumor models” in the lab. The goal is to see how these models respond to new therapies, which may help guide more effective treatment choices in the future.
This study looks for signs in your tumor that can predict how well anti–PD-1 immunotherapy will work for certain head and neck cancers. You may benefit by helping doctors match the right treatment to the right patients.
This study collects blood and tumor tissue samples to analyze biological markers in patients with advanced head and neck squamous cell carcinoma before starting immunotherapy. The goal is to better understand how these markers relate to treatment response.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a new approach that combines radiation and immunotherapy, while trying to protect your immune cells. It is for people with head and neck cancer that has not spread across the midline of the body and has not been treated yet.
Hear when a new Squamous Cell Carcinoma of the Oropharynx trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.